These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2200748)

  • 1. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2.
    Ruby J; Brinkman C; Jones S; Ramshaw I
    Immunol Cell Biol; 1990 Apr; 68 ( Pt 2)():113-7. PubMed ID: 2200748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein.
    Dallo S; Maa JS; Rodriguez JR; Rodriguez D; Esteban M
    Virology; 1989 Nov; 173(1):323-9. PubMed ID: 2510402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
    J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
    Graham BS; Gorse GJ; Schwartz DH; Keefer MC; McElrath MJ; Matthews TJ; Wright PF; Belshe RB; Clements ML; Dolin R
    J Infect Dis; 1994 Oct; 170(4):782-6. PubMed ID: 7930718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.
    Cooney EL; Collier AC; Greenberg PD; Coombs RW; Zarling J; Arditti DE; Hoffman MC; Hu SL; Corey L
    Lancet; 1991 Mar; 337(8741):567-72. PubMed ID: 1671940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
    Graham BS; Belshe RB; Clements ML; Dolin R; Corey L; Wright PF; Gorse GJ; Midthun K; Keefer MC; Roberts NJ
    J Infect Dis; 1992 Aug; 166(2):244-52. PubMed ID: 1353102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Kliks S; Wright PF
    J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
    Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
    AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
    Klaniecki J; Dykers T; Travis B; Schmitt R; Wain M; Watson A; Sridhar P; McClure J; Morein B; Ulrich JT
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):791-8. PubMed ID: 1742074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
    Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
    Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
    Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.